MentionFox
Home › Executive changes › Barinthus Biotherapeutics plc.
Leadership changes · SEC Form 8-K, Item 5.02

Barinthus Biotherapeutics plc. executive changes

Every leadership change Barinthus Biotherapeutics plc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Appointments named1
Latest filing2026-04-22

Barinthus Biotherapeutics plc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-04-22. Between them they name 1 person. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-04-22 · 8-K

Appointed: Douglas Swirsky, Chief Financial Officer, effective 2026-05-01

On April 22, 2026, the board of directors of Barinthus Biotherapeutics plc (the "Company") appointed Douglas Swirsky as Chief Financial Officer and principal accounting officer of the Company, effective as of May 1, 2026 (the "Appointment").
Filed 2026-03-31 · 8-K

Reported

On March 27, 2026, Ms. Jones notified the Company that she will step down as the Company's principal accounting officer, effective as of April 30, 2026.
Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at Barinthus Biotherapeutics plc., with the record behind each one.

Find candidates like Chief Financial Officer at Barinthus Biotherapeutics plc.
Selling to Barinthus Biotherapeutics plc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Barinthus Biotherapeutics plc. is in the news or changes leadership.

Get an alert when Barinthus Biotherapeutics plc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Barinthus Biotherapeutics plc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/barinthus-biotherapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Barinthus Biotherapeutics plc. (BRNS) executive changes: Douglas Swirsky appointed, Chief Financial Officer. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/barinthus-biotherapeutics